Andrew Steven Allegretti, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatorenal Syndrome | 12 | 2023 | 60 | 6.160 |
Why?
|
| Acute Kidney Injury | 17 | 2023 | 1887 | 4.080 |
Why?
|
| Liver Cirrhosis | 8 | 2023 | 1757 | 2.080 |
Why?
|
| Vasoconstrictor Agents | 7 | 2022 | 628 | 1.750 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 3 | 2021 | 89 | 1.390 |
Why?
|
| Lypressin | 5 | 2022 | 22 | 1.320 |
Why?
|
| Hemofiltration | 2 | 2020 | 61 | 1.310 |
Why?
|
| Kidney Failure, Chronic | 6 | 2021 | 2547 | 1.050 |
Why?
|
| Renal Insufficiency, Chronic | 11 | 2023 | 1986 | 0.980 |
Why?
|
| Renal Dialysis | 5 | 2020 | 1743 | 0.920 |
Why?
|
| Micropore Filters | 1 | 2020 | 23 | 0.820 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2021 | 63 | 0.810 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2020 | 172 | 0.740 |
Why?
|
| Pyrans | 1 | 2019 | 59 | 0.710 |
Why?
|
| Glomerular Filtration Rate | 7 | 2023 | 2104 | 0.700 |
Why?
|
| Renal Replacement Therapy | 3 | 2021 | 255 | 0.690 |
Why?
|
| Cholestasis | 1 | 2021 | 360 | 0.670 |
Why?
|
| Angiopoietin-2 | 1 | 2019 | 168 | 0.660 |
Why?
|
| Liver Transplantation | 5 | 2023 | 2019 | 0.610 |
Why?
|
| Sickle Cell Trait | 4 | 2021 | 78 | 0.580 |
Why?
|
| Paracentesis | 1 | 2016 | 94 | 0.560 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 307 | 0.530 |
Why?
|
| Drug Monitoring | 1 | 2020 | 939 | 0.510 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2014 | 77 | 0.510 |
Why?
|
| Acid-Base Equilibrium | 1 | 2015 | 185 | 0.510 |
Why?
|
| Lectins | 1 | 2016 | 560 | 0.500 |
Why?
|
| Bicarbonates | 1 | 2015 | 311 | 0.490 |
Why?
|
| Heparin | 1 | 2020 | 1620 | 0.470 |
Why?
|
| Liver Diseases | 1 | 2021 | 1243 | 0.460 |
Why?
|
| Calciphylaxis | 1 | 2014 | 124 | 0.450 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2014 | 362 | 0.410 |
Why?
|
| Kidney | 6 | 2022 | 6882 | 0.400 |
Why?
|
| Intensive Care Units | 3 | 2023 | 3451 | 0.380 |
Why?
|
| Living Donors | 1 | 2014 | 573 | 0.380 |
Why?
|
| Critical Illness | 2 | 2023 | 2529 | 0.350 |
Why?
|
| Anemia, Sickle Cell | 3 | 2021 | 978 | 0.330 |
Why?
|
| Albumins | 2 | 2022 | 564 | 0.310 |
Why?
|
| Gastric Bypass | 1 | 2014 | 744 | 0.290 |
Why?
|
| Nurses | 1 | 2015 | 2376 | 0.290 |
Why?
|
| Chronic Disease | 3 | 2019 | 9034 | 0.280 |
Why?
|
| Humans | 51 | 2023 | 715818 | 0.260 |
Why?
|
| Obesity, Morbid | 1 | 2014 | 1087 | 0.250 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 2473 | 0.250 |
Why?
|
| Middle Aged | 23 | 2022 | 214666 | 0.240 |
Why?
|
| Creatinine | 2 | 2020 | 1898 | 0.230 |
Why?
|
| Male | 29 | 2022 | 350352 | 0.230 |
Why?
|
| Taste Disorders | 1 | 2022 | 36 | 0.220 |
Why?
|
| Prognosis | 6 | 2023 | 29007 | 0.220 |
Why?
|
| Low Back Pain | 1 | 2010 | 934 | 0.210 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2021 | 72 | 0.210 |
Why?
|
| Exercise | 1 | 2018 | 5427 | 0.210 |
Why?
|
| Feces | 2 | 2017 | 1378 | 0.210 |
Why?
|
| Female | 28 | 2022 | 377229 | 0.210 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2021 | 61 | 0.210 |
Why?
|
| Clostridium Infections | 2 | 2017 | 507 | 0.210 |
Why?
|
| Kidney Transplantation | 2 | 2021 | 4140 | 0.200 |
Why?
|
| Receptors, Purinergic P2Y | 1 | 2020 | 24 | 0.200 |
Why?
|
| Aged | 18 | 2022 | 162468 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 3959 | 0.190 |
Why?
|
| Treatment Outcome | 9 | 2022 | 62040 | 0.190 |
Why?
|
| Physicians | 2 | 2015 | 4375 | 0.190 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2021 | 86 | 0.190 |
Why?
|
| Factor Xa | 1 | 2020 | 162 | 0.190 |
Why?
|
| Olfaction Disorders | 1 | 2022 | 198 | 0.180 |
Why?
|
| Ferrosoferric Oxide | 1 | 2021 | 379 | 0.180 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2021 | 199 | 0.180 |
Why?
|
| Clinical Competence | 1 | 2015 | 4630 | 0.180 |
Why?
|
| Hypertension, Portal | 1 | 2021 | 222 | 0.180 |
Why?
|
| Bile Acids and Salts | 1 | 2021 | 355 | 0.180 |
Why?
|
| Equipment Failure Analysis | 1 | 2020 | 863 | 0.160 |
Why?
|
| Prospective Studies | 7 | 2021 | 51317 | 0.160 |
Why?
|
| DNA, Bacterial | 2 | 2019 | 1534 | 0.150 |
Why?
|
| Massachusetts | 3 | 2019 | 8743 | 0.150 |
Why?
|
| Communication | 1 | 2010 | 3516 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2010 | 3318 | 0.150 |
Why?
|
| Hyponatremia | 1 | 2019 | 305 | 0.150 |
Why?
|
| Cohort Studies | 7 | 2023 | 40032 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 3902 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 11090 | 0.140 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 175 | 0.130 |
Why?
|
| Elastic Modulus | 1 | 2015 | 219 | 0.130 |
Why?
|
| Blood Coagulation | 1 | 2020 | 1110 | 0.130 |
Why?
|
| Proxy | 1 | 2015 | 145 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2020 | 1473 | 0.130 |
Why?
|
| Poison Control Centers | 1 | 2014 | 70 | 0.130 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2021 | 1455 | 0.120 |
Why?
|
| Adult | 16 | 2021 | 212279 | 0.120 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2017 | 335 | 0.120 |
Why?
|
| Case-Control Studies | 4 | 2021 | 21795 | 0.120 |
Why?
|
| Sodium | 1 | 2019 | 1599 | 0.120 |
Why?
|
| Anemia | 1 | 2023 | 1419 | 0.120 |
Why?
|
| Carrier State | 1 | 2017 | 538 | 0.120 |
Why?
|
| Length of Stay | 2 | 2020 | 6270 | 0.120 |
Why?
|
| Waiting Lists | 1 | 2017 | 715 | 0.120 |
Why?
|
| Bumetanide | 1 | 2013 | 97 | 0.120 |
Why?
|
| Hemoglobins | 1 | 2019 | 1502 | 0.120 |
Why?
|
| Hospital Mortality | 2 | 2020 | 5141 | 0.120 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 263 | 0.120 |
Why?
|
| Diagnostic Errors | 1 | 2020 | 1267 | 0.120 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 15911 | 0.110 |
Why?
|
| Poisoning | 1 | 2014 | 247 | 0.110 |
Why?
|
| Hospital Charges | 1 | 2014 | 362 | 0.110 |
Why?
|
| Hip Fractures | 1 | 2019 | 877 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2014 | 15102 | 0.100 |
Why?
|
| Ischemia | 1 | 2020 | 1906 | 0.100 |
Why?
|
| Abdominal Pain | 1 | 2017 | 1026 | 0.100 |
Why?
|
| Carbon Dioxide | 1 | 2015 | 1130 | 0.100 |
Why?
|
| Diuretics | 1 | 2013 | 588 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2021 | 72473 | 0.090 |
Why?
|
| Disease Progression | 3 | 2023 | 13215 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 2597 | 0.090 |
Why?
|
| Diarrhea | 1 | 2017 | 1372 | 0.090 |
Why?
|
| Neoplasms | 1 | 2018 | 20528 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2014 | 1879 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 13219 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 11201 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2021 | 10503 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 2058 | 0.080 |
Why?
|
| Risk Factors | 6 | 2023 | 70879 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2019 | 3279 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 19537 | 0.070 |
Why?
|
| Patient Readmission | 1 | 2020 | 2980 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2020 | 4375 | 0.070 |
Why?
|
| Double-Blind Method | 1 | 2019 | 11945 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 5463 | 0.070 |
Why?
|
| Time Factors | 2 | 2017 | 40887 | 0.060 |
Why?
|
| Patients | 1 | 2010 | 773 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2019 | 5065 | 0.060 |
Why?
|
| Health Status | 1 | 2017 | 4001 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 9596 | 0.060 |
Why?
|
| African Americans | 1 | 2019 | 5003 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2010 | 2596 | 0.060 |
Why?
|
| Comorbidity | 1 | 2017 | 10435 | 0.060 |
Why?
|
| Sepsis | 1 | 2016 | 2465 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12483 | 0.060 |
Why?
|
| Hypertension | 1 | 2022 | 8270 | 0.060 |
Why?
|
| Age Factors | 1 | 2019 | 18787 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 12460 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 7313 | 0.050 |
Why?
|
| Hemoglobin, Sickle | 1 | 2019 | 115 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2010 | 1460 | 0.050 |
Why?
|
| Ascites | 1 | 2021 | 341 | 0.050 |
Why?
|
| Extracellular Fluid | 1 | 2019 | 168 | 0.040 |
Why?
|
| Midodrine | 1 | 2017 | 23 | 0.040 |
Why?
|
| Indiana | 1 | 2017 | 92 | 0.040 |
Why?
|
| United States | 3 | 2021 | 67910 | 0.040 |
Why?
|
| Neutrophil Infiltration | 1 | 2020 | 400 | 0.040 |
Why?
|
| Octreotide | 1 | 2017 | 148 | 0.040 |
Why?
|
| Hospitalization | 1 | 2016 | 9745 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 58326 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 2022 | 1219 | 0.040 |
Why?
|
| Gadolinium | 1 | 2021 | 910 | 0.040 |
Why?
|
| Chemokines | 1 | 2020 | 962 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 39305 | 0.040 |
Why?
|
| Metagenomics | 1 | 2019 | 415 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2019 | 917 | 0.030 |
Why?
|
| Norepinephrine | 1 | 2017 | 912 | 0.030 |
Why?
|
| Urinalysis | 1 | 2017 | 366 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 23437 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2019 | 8075 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 855 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 1073 | 0.030 |
Why?
|
| Genes, Bacterial | 1 | 2017 | 1136 | 0.030 |
Why?
|
| Elasticity | 1 | 2015 | 655 | 0.030 |
Why?
|
| Nephrotic Syndrome | 1 | 2017 | 385 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 14438 | 0.030 |
Why?
|
| RNA | 1 | 2022 | 2613 | 0.030 |
Why?
|
| Acute Disease | 1 | 2023 | 7142 | 0.030 |
Why?
|
| International Cooperation | 1 | 2018 | 1438 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 2677 | 0.030 |
Why?
|
| HIV Infections | 1 | 2017 | 15784 | 0.030 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2015 | 366 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 1124 | 0.020 |
Why?
|
| Monocytes | 1 | 2020 | 2620 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2021 | 2929 | 0.020 |
Why?
|
| Dopamine | 1 | 2017 | 1593 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2017 | 1315 | 0.020 |
Why?
|
| Mortality | 1 | 2021 | 2837 | 0.020 |
Why?
|
| Fibrosis | 1 | 2015 | 1928 | 0.020 |
Why?
|
| Cost Savings | 1 | 2014 | 916 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 2292 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2021 | 23476 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 6274 | 0.020 |
Why?
|
| Contrast Media | 1 | 2021 | 5276 | 0.020 |
Why?
|
| Neutrophils | 1 | 2020 | 3800 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2019 | 3579 | 0.020 |
Why?
|
| Survival Rate | 1 | 2021 | 13213 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2017 | 2124 | 0.020 |
Why?
|
| Recurrence | 1 | 2017 | 8240 | 0.020 |
Why?
|
| Prevalence | 1 | 2022 | 14912 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2020 | 15058 | 0.020 |
Why?
|
| Sex Factors | 1 | 2019 | 10666 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2017 | 5922 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 8048 | 0.010 |
Why?
|
| Young Adult | 2 | 2019 | 56228 | 0.010 |
Why?
|
| Adolescent | 2 | 2019 | 85157 | 0.010 |
Why?
|
| Algorithms | 1 | 2018 | 13758 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2014 | 24796 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 20357 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 80373 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 34430 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 34569 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2014 | 41198 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 169404 | 0.010 |
Why?
|
| Child | 1 | 2014 | 74468 | 0.000 |
Why?
|